Table 1.
Characteristics of 95 patients with locoregionally recurrent, metastatic, or secondary lung tumors re‐irradiated with carbon‐ion radiotherapy
| Characteristic | Patients (n = 95) |
|---|---|
| Sex, n (%) | |
| Male | 64 (67.4) |
| Female | 31 (32.6) |
| Performance status, n (%) | |
| 0 | 63 (66.3) |
| 1 | 29 (30.5) |
| 2 | 3 (3.2) |
| Smoking status, n (%) | |
| Smoker/ex‐smoker | 42 (44.2) |
| Non‐smoker | 49 (51.6) |
| Unknown | 4 (4.2) |
| Pulmonary emphysema, n (%) | |
| Y | 17 (17.9) |
| N | 78 (82.1) |
| Interstitial pneumonia, n (%) | |
| Y | 7 (7.4) |
| N | 88 (92.6) |
| cStage at initial irradiation, n (%) | |
| Primary lung cancer | 73 (76.8) |
| IA | 22 (23.2) |
| IB | 32 (33.7) |
| IIA | 4 (4.2) |
| IIB | 2 (2.1) |
| IIIA | 3 (3.2) |
| IIIB | 1 (1.0) |
| Recurrent or residual cancer after S/CT | 9 (9.4) |
| Metastatic lung cancer | 21 (22.1) |
| Other | 1 (1.0) |
| Histology of primary lung cancer, n (%) | |
| SCC | 20 (27.4) |
| ADC | 42 (57.5) |
| LCC | 1 (1.4) |
| NSCLC | 4 (5.5) |
| Unknown | 6 (8.2) |
| Age at re‐irradiation, years; median (range) | 74 (37‐93) |
| Interval between initial irradiation and re‐irradiation, months; median (range) | 17 (6‐139) |
| Follow‐up after re‐irradiation, months; median (range) | 18 (1‐89) |
| Initial irradiation dose, Gy (RBE); median | 52.8 |
| Site of failure at re‐irradiation, n (%) | |
| In‐field | 70 (73.7) |
| Marginal zone | 24 (25.3) |
| In‐field (primary site) and out‐of‐field (MLN) | 1 (1.0) |
| Re‐irradiation dose, Gy (RBE); median | 66.0 |
| Re‐irradiation site, n (%) | |
| Lung | 77 (81.1) |
| MLN | 13 (13.7) |
| Lung and MLN | 4 (4.2) |
| PM | 1 (1.0) |
| Re‐irradiation field, n (%) | |
| Central | 17 (17.9) |
| Peripheral | 78 (82.1) |
| CTV for re‐irradiation, mL; median (range) | 79.5 (7.1‐452.8) |
ADC, adenocarcinoma; cStage, clinical Stage; CT, chemotherapy; CTV, clinical target volume; LCC, large cell carcinoma; MLN, mediastinal lymph node; N, no; NSCLC, non‐small‐cell lung cancer; PM, pleural metastasis; RBE, relative biological effectiveness; S, surgery; SCC, squamous cell carcinoma; Y, yes.